Bone Biologics (BBLG) Liabilities and Shareholders Equity (2012 - 2025)

Bone Biologics (BBLG) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $5.8 million in Q4 2025.

• Liabilities and Shareholders Equity for Q4 2025 came in at $5.8 million, up 50.11% year-over-year; the trailing twelve-month figure through Dec 2025 was $22.3 million (up 49.14% YoY), and the FY2025 annual result was $5.8 million, up 50.11% from the prior year.
• Liabilities and Shareholders Equity fell to $5.8 million in Q4 2025 per BBLG's latest filing, from $6.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $8.5 million in Q4 2022 and troughed at $4438.0 in Q2 2021.
• A 5-year average of $4.6 million and a median of $5.1 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 127409.71% in 2022, then plunged 58.11% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $6.7 million in 2021, then gained by 27.26% to $8.5 million in 2022, then slumped by 56.0% to $3.7 million in 2023, then rose by 3.31% to $3.9 million in 2024, then soared by 50.11% to $5.8 million in 2025.
• Business Quant data shows BBLG's Liabilities and Shareholders Equity at $5.8 million in Q4 2025, $6.4 million in Q3 2025, and $7.0 million in Q2 2025.